Target intelligence / Profile preview

Reticulocalbin-1 (RCN1)

Target
RCN1
Molecular classification
Calcium-binding protein, CREC family (Cab45, reticulocalbin, ERC-55, calumenin), ER resident protein, EF-hand domain protein
01

Overview

Reticulocalbin-1 (RCN1) is an endoplasmic reticulum-resident calcium-binding protein from the CREC family, distinguished by six EF-hand domains and an HDEL ER retention signal. RCN1 regulates intracellular calcium homeostasis, modulates the unfolded protein response during ER stress, and inhibits stress-induced apoptosis through direct interaction with the inositol 1,4,5-trisphosphate receptor 1 (IP3R1). It also operates as a microglial phagocytosis ligand, facilitating the clearance of apoptotic cells, and is linked to cell proliferation and tumor progression, notably in oral, breast, and colorectal cancers. RCN1 expression in the plasma membrane is increased under certain stimuli, such as tumor necrosis factor alpha, and aberrant RCN1 expression or deletion affects development and disease, making it a possible biomarker and therapeutic target.

Other names
Reticulocalbin-1RCN1RCNRcalPIG20FLJ37041Proliferation-inducing gene 20HEL-S-84RCALEpididymis secretory protein Li 84
02

Mechanism of action

Suppression of ER stress-induced apoptosis via inhibition of ER calcium release and regulation of UPR signaling, specifically PERK- and IRE1-mediated pathways. Facilitates microglial phagocytosis by serving as a ligand for apoptotic cells.

03

Biological functions

Intracellular calcium homeostasisRegulation of cell proliferationRegulation of apoptosisModulation of ER stress and unfolded protein response (UPR)Phagocytosis ligand for microglia (promoting clearance of apoptotic cells)
04

Disease associations

Cancer (oral squamous cell carcinoma, breast cancer, colorectal cancer, kidney cancer, liver cancer)Limb-girdle muscular dystrophyNephrogenic systemic fibrosis
05

Safety considerations

As RCN1 is involved in essential processes of cellular calcium homeostasis and apoptosis, targeting RCN1 therapeutically may pose safety challenges related to interference with normal cell survival, homeostasis, and immune surveillance
06

Interacting drugs

No interacting drugs are currently identified in the literature for RCN1; it is mainly studied as a disease biomarker and as a candidate for future therapeutic targeting
07

Biomarkers

Overexpression of RCN1 is a marker of poor prognosis in oral squamous cell carcinoma and kidney clear cell carcinomaUpregulation correlated with multiple cancer types

Beyond the preview

Go deeper on Reticulocalbin-1 (RCN1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Reticulocalbin-1 (RCN1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call